Increased myeloperoxidase plasma levels in patients with alzheimer's disease

Journal of Alzheimer's Disease

Volumn 39, Issue 3, 2014, Pages 557-564

  Tzikas, Stergios ^a   Schlak, Dennis ^b   Sopova, Kateryna ^c   Gatsiou, Aikaterini ^c   Stakos, Dimitrios ^f   Stamatelopoulos, Kimon ^e   Stellos, Konstantinos ^c   Laske, Christoph ^c,d,g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF ATHENS   (Greece)

^f DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^g GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; amyloid ; dementia; myeloperoxidase

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MYELOPEROXIDASE;

AGED; ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ALZHEIMER'S DISEASE; AMYLOID-Β; DEMENTIA; MYELOPEROXIDASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PEROXIDASE; ROC CURVE;

EID: 84894204690     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131469     Document Type: Article

References (49)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
3. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brick-man AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
4. Roselli F, Tartaglione B, Federico F, Lepore V, Defazio G, Livrea P (2009) Rate of MMSE score change in Alzheimer's disease: Influence of education and vascular risk factors. Clin Neurol Neurosurg 111, 327-330.
5. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH (2002) The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertensionin Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052.
6. Deschaintre Y, Richard F, Leys D, Pasquier F (2009) Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73, 674-680.
7. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
8. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 8, 26.
9. Laske C, Sopova K, Stellos K (2012) Platelet activation in Alzheimer's disease: From pathophysiology to clinical value. Curr Vasc Pharmacol 10, 626-630.
10. Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C (2012) Association of platelet activation with vascular cognitive impairment: Implications in dementia development? Curr Vasc Pharmacol, 2012 Jan 20. [Epub ahead of print].
11. Stellos K, Panagiota V, Kogel A, Leyhe T, Gawaz M, Laske C (2010) Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J Cereb Blood Flow Metab 30, 1817-1820.
12. Laske C, Leyhe T, Stransky E, Eschweiler GW, Bueltmann A, Langer H, Stellos K, Gawaz M (2008) Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. J Psychiatr Res 42, 746-751.
13. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Schel-tens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
15. Stellos K, Panagiota V, Sachsenmaier S, Trunk T, Straten G, Leyhe T, Seizer P, Geisler T, Gawaz M, Laske C (2010) Increased circulating progenitor cells in Alzheimer's disease patients with moderate to severe dementia: Evidence for vascular repair and tissue regeneration? J Alzheimers Dis 19, 591-600.
16. Bigalke B, Schreitmuller B, Sopova K, Paul A, Stransky E, Gawaz M, Stellos K, Laske C (2011) Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 6, e20286.
17. Lefkowitz DL, Mone J, Lefkowitz SS (2010) Myeloperoxi-dase: The good, the bad, and the ugly. Curr Immunol Rev 6, 123-129.
18. Libby P (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
19. Podrez EA, Abu-Soud HM, Hazen SL (2000) Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28, 1717-1725.
20. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296, 2391-2394.
21. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E (1999) Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155, 31-41.
22. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, Heinecke JW (2004) Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neu-rochem 90, 724-733.
23. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, Alafuzoff I, Soininen H (2000) MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 55, 1284-1290.
24. Crawford FC, Freeman MJ, Schinka JA, Morris MD, Abdullah LI, Richards D, Sevush S, Duara R, Mullan MJ (2001) Association between Alzheimer's disease and a functional polymorphism in the Myeloperoxidase gene. Exp Neurol 167, 456-459.
25. Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, Reynolds WF (2009) Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem 284, 3158-3169.
26. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grod-stein F (2012) Plasma amyloid-betaas apredictor ofdementia and cognitive decline:Asystematic review and meta-analysis. Arch Neurol 69, 824-831.
27. Peters FT (2007) Stability of analytes in biosamples-an important issue in clinical and forensic toxicology? Anal Bioanal Chem 388, 1505-1519.
28. Wendland AE, Camargo JL, Polanczyk CA (2010) Effect of preanalytical variables on myeloperoxidase levels. Clin Chim Acta 411, 1650-1655.
29. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effectsof rofecoxibor naproxenvsplacebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819-2826.
30. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905.
31. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808.
32. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyket-sos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN (2011) Extended results of the Alzheimer's disease anti-inflammatoryprevention trial. Alzheimers Dement 7, 402-411.
33. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW, Investigators C (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440-1445.
34. Brennan M-LL, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349, 1595-1604.
35. Rudolph V, Keller T, Schulz A, Ojeda F, Rudolph TK, Tzikas S, Bickel C, Meinertz T, Munzel T, Blankenberg S, Baldus S (2012) Diagnostic and prognostic performance of myeloper-oxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain.Circ Cardiovasc Genet 5, 561-568.
36. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG (2009) Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin Chem 55, 1462-1470.
37. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, Brummer J, Rudolph V, Munzel T, Heitzer T, Meinertz T, Baldus S (2005) Myeloperoxidase mediates neu-trophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 102, 431-436.
38. Lau D, Baldus S (2006) Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 111, 16-26.
39. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
40. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
41. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL (2003) Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696.
42. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, Leyhe T, Stellos K (2010) Amyloid-beta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's diseasepatients.J Alzheimers Dis21, 1263-1269.
43. Vasan RS (2006) Biomarkers of cardiovascular disease: Molecular basisand practical considerations.Circulation113, 2335-2362.
44. Laske C, Sopova K, Hoffmann N, Stransky E, Hagen K, Fall-gatter AJ, Stellos K, Leyhe T (2011) Stem cell factor plasma levels are decreased in Alzheimer's disease patients with fast cognitive decline after one-year follow-up period: The Pythia-study. J Alzheimers Dis 26, 39-45.
45. Laske C, Stellos K, Stransky E, Seizer P, Akcay O, Eschweiler GW, Leyhe T, Gawaz M (2008) Decreased plasma and cere-brospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J Alzheimers Dis 15, 451-460.
46. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T (2011) Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 14, 399-404.
47. Laske C, Stellos K, Stransky E, Leyhe T, Gawaz M (2009) Decreased plasma levels of granulocyte-colony stimulating factor (G-CSF) in patients with early Alzheimer's disease. J Alzheimers Dis 17, 115-123.
48. Laske C, Stellos K, Eschweiler GW, Leyhe T, Gawaz M (2008) Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: A contribution to a deficient hematopoi-etic brain support? J Alzheimers Dis 15, 83-95.
49. Vita JA, Brennan M-LL, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF, Hazen SL (2004) Serummyeloperoxidaselevelsindependentlypredictendothe-lial dysfunction in humans. Circulation 110, 1134-1139.